JOURNAL BROWSE
Search
Advanced SearchSearch Tips
The Incidence Rate of Lymphadenitis after Bacille Calmette-Guérin (BCG) Vaccination
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Pediatric Infection and Vaccine
  • Volume 23, Issue 1,  2016, pp.54-61
  • Publisher : The Korean Society of Pediatric Infectious Diseases
  • DOI : 10.14776/piv.2016.23.1.54
 Title & Authors
The Incidence Rate of Lymphadenitis after Bacille Calmette-Guérin (BCG) Vaccination
Kim, Jaehong; Lee, Kyujin; Kim, Jong-Hyun; Kim, Seong Joon; Lee, Soo Young; Lee, Hye Jin; Cho, Kyung Soon; Kwon, Young Joo; Lee, Byoung Chan; Jo, Sang Min; Ha, Jeong Hun; Lee, Yoon Kyung; Seung, So Jin;
  PDF(new window)
 Abstract
Purpose: Bacille Calmette- (BCG) lymphadenitis is a relatively frequent local adverse reactions after BCG vaccination. Its incidence rate is usually <1%. However, this rate may be different according to BCG strain, vaccination method or skill, etc. In the Republic of Korea, two BCG strains are used: intradermal Danish-1331 or percutaneous Tokyo-172. We surveyed the incidence rates of BCG lymphadenitis. Methods: This survey was performed in total 25 centers (5 general hospitals, 20 private pediatric clinics). Immunized type of BCG strain in study subjects was verified by directly observing the scar. The occurrence of BCG lymphadenitis was asked to their parent. In cases of BCG lymphadenitis, location, diameter size, progression of suppuration, and treatment method were investigated, as well. Results: The total number of study subjects was 3,342. Among these, the subjects suitable for enrollment criteria (total 3,222; Tokyo strain 2,501, Danish strain 721) were analyzed. BCG lymphadenitis regardless of its size developed in each five of subjects per strains, therefore, its incidence rate was 0.20% in Tokyo and 0.69% in Danish strain, respectively (P
 Keywords
Bacille Calmette Guerin (BCG);lymphadenitis;adverse reaction;Dannish strain;Tokyo strain;
 Language
Korean
 Cited by
 References
1.
World Health Organization. BCG vaccine: WHO position paper. Wkly Epidemiol Rec 2004;79:27-38.

2.
Milstien JB, Gibson JJ. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 1990;68:93-108.

3.
The Korean Pediatric Society. BCG vaccine. In: Lee HJ, editor. Immunization guideline. 7th ed. Seoul: The Korean Pediatric Society; 2012:40-54.

4.
Lotte A, Wasz-Hockert O, Poisson N, Dumitrescu N, Verron M, Couvet E. A bibliography of the complications of BCG vaccination. A comprehensive list of the world literature since the introduction of BCG up to July 1982, supplemented by over 100 personal communications. Adv Tuberc Res 1984;21:194-245.

5.
World Health Organization. Immunization safety surveillance. Guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. Manila: Western Pacific Regional Office, WHO,1999.

6.
Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 1997;24:1139-46. crossref(new window)

7.
Ustvedt HJ. Local reactions in BCG vaccination. Bull World Health Organ 1950;2:441-68.

8.
Goraya JS, Virdi VS. Bacille Calmette-Guerin lymphadenitis. Postgrad Med J 2002;78:327-9. crossref(new window)

9.
Mori T, Yamauchi Y, Shiozawa K. Lymph node swelling due to bacille Camette-Guerin vaccination with multipuncture method. Tuber Lung Dis 1996;77:269-73. crossref(new window)

10.
Daoud W. Control of an outbreak of BCG complications in Gaza. Respirology 2003;8:376-8. crossref(new window)

11.
Jeena PM, Chhagan MK, Topley J, Coovadia HM. Safety of the intradermal Copenhagen 1331 BCG vaccine in neonates in Durban, South Africa. Bull World Health Organ 2001;79:337-43.

12.
R Core Team (2015). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: https://www.R-project.org/. Assessed 26 October 2015.

13.
Corbel MJ, Fruth U, Griffiths E, Knezevic I. Report on a WHO consultation on the characterisation of BCG strains, Imperial College, London 15-16 December 2003. Vaccine 2004;22:2675-80. crossref(new window)

14.
Smith KC, Orme IM, Starke JR. Tuberculosis vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Elsevier Inc, 2013:789-811.

15.
Fine PEM, Carneiro IAM, Milstien JB, Clements CJ. Issues relating to the use of BCG in immunization programmes: a discussion document. Geneva: WHO; 1999.

16.
Samileh N, Ahmad S, Farzaneh A, Shahnaz R, Lida F, Mohammad N. Immunity status in children with Bacille Calmette-Guerin adenitis. A prospective study in Tehran, Iran. Saudi Med J 2006;27:1719-24.

17.
Serour F, Mizrahi A, Somekh E, Feinberg J, Picard C, Casanova JL, et al. Analysis of the interleukin-12/interferongamma pathway in children with non-tuberculous mycobacterial cervical lymphadenitis. Eur J Pediatr 2007;166:835-41. crossref(new window)

18.
Yeganeh M, Heidarzade M, Pourpak Z, Parvaneh N, Rezaei N, Gharagozlou M, et al. Severe combined immunodeficiency:a cohort of 40 patients. Pediatr Allergy Immunol 2008;19:303-6. crossref(new window)

19.
Lee PP, Chan KW, Jiang L, Chen T, Li C, Lee TL, et al. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr Infect Dis J 2008;27:224-30. crossref(new window)

20.
Nyerges G, Drinoczy M. Significance of the number of viable units in BCG vaccines. Dev Biol Stand 1986;58:331-6.

21.
Teulieres L, Diouf MA, Chaud P, Saint-Cyr A, Saliou P. Comparative trial of administration of half (0.05 mg) and quarter (0.025 mg) dose of intradermal Pasteur BCG on 291 infants from birth to 1 year in French Guyana. Vaccine 1991;9:521-4. crossref(new window)

22.
Teo SS, Smeulders N, Shingadia DV. BCG vaccine-associated suppurative lymphadenitis. Vaccine 2005;23:2676-9. crossref(new window)

23.
Gheorghiu M. The present and future role of BCG vaccine in tuberculosis control. Biologicals 1990;18:135-41. crossref(new window)

24.
Bolger T, O'Connell M, Menon A, Butler K. Complications associated with the bacille Calmette-Guerin vaccination in Ireland. Arch Dis Child 2006;91:594-7.

25.
World Health Organization. Expanded programme on immunization, biologicals unit: lymphadenitis associated with BCG immunization. Wkly Epidemiol Rec 1988;63:381-8.

26.
Baek HS, Chang JY, Moon SJ, Oh SH. Lymphadenitis following intradermal BCG vaccination. Korean J Pediatr 2006;49:46-50. crossref(new window)

27.
Hwang JS, Choi YY, Ma JS, Hwang TJ. A clinical study on BCG lymphadenitis. Korean J Pediatr 1997;40:614-8.

28.
Lee JS, Sohn YM. Observation of response to PPD skin test and local side reactions at multiple inoculation sites after percutaneous inoculation with BCG Tokyo 172 strain. Korean J Pediatr Infect Dis 2000;7:201-10.

29.
Oh MH, Kim KH, Sim JG. The clinical study on conversion rate of Mantoux test, change of local lesion and complication after multipuncture BCG vaccination in neonates. Korean J Pediatr 1997;40:1120-30.

30.
Kim HJ, Oh SY, Lee JB. Comparison of each strains (Pasteur, Danish, Tokyo) of BCG efficacy using tuberculin test and adverse reactions. Korea Center for Diseases Control and Prevention, Osong, 2008.

31.
Goraya JS, Virdi VS. Treatment of Calmette-Guerin Bacillus adenitis: a metaanalysis. Pediatr Infect Dis J 2001;20:632-4. crossref(new window)

32.
Banani SA, Alborzi A. Neddle aspiration for suppurative post-BCG adenitis. Arch Dis Child 1994;71:446-7. crossref(new window)